STOCK TITAN
  1. Home
  2. Sec-filings
  3. DFTX
  4. [144] Definium Therapeutics, Inc. SEC Filing

Definium holder plans $718K Rule 144 share sale

Shareholder Robert B. Barrow files a Rule 144 notice to sell 19,023 DFTX shares valued at about $718,000 after recent equity compensation and prior sales.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Definium Therapeutics, Inc. (DFTX) is the subject of a notice that shareholder Robert B. Barrow intends to sell 19,023 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $718,144.88 as of the planned sale date of September 3, 2026.

These shares are tied to Performance Stock Units acquired from the issuer as compensation for services rendered on September 3, 2026, and follow a prior sale of 29,208 shares for $1,230,533.04 during the past three months.

Positive

  • None.

Negative

  • None.
Shares to be sold under Rule 144 19,023 shares Planned sale of Definium Therapeutics, Inc. common stock
Aggregate market value of planned sale $718,144.88 Value of 19,023 shares of DFTX common stock
Shares outstanding 134,366,950 shares Definium Therapeutics, Inc. common stock outstanding
Shares sold in prior 3 months 29,208 shares Sale on June 25, 2026 by Robert B. Barrow
Aggregate value of prior 3‑month sale $1,230,533.04 Value of 29,208 DFTX shares sold on June 25, 2026
Date acquired for current block September 3, 2026 Acquisition date of Performance Stock Units underlying 19,023 shares
Approximate date of sale September 3, 2026 Planned sale date for 19,023 shares under Rule 144
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Performance Stock Units financial
"Common | 09/03/2026 | Performance Stock Units | Issuer"
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
aggregate market value financial
"Common | Morgan Stanley Smith Barney LLC ... | 19023 | 718144.88"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
services rendered financial
"19023 | 09/03/2026 | Services Rendered"

FAQ

What does the Form 144 filing disclose for Definium Therapeutics, Inc. (DFTX)?
It discloses that Robert B. Barrow plans to sell 19,023 shares of DFTX common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $718,144.88, based on information as of September 3, 2026.

How many Definium Therapeutics (DFTX) shares is Robert B. Barrow planning to sell?
Robert B. Barrow plans to sell 19,023 shares of Definium Therapeutics, Inc. common stock under Rule 144, with an indicated aggregate market value of $718,144.88 at the time of the notice.

What type of securities are covered in this DFTX Form 144 filing?
The filing covers common stock of Definium Therapeutics, Inc. related to Performance Stock Units acquired from the issuer on September 3, 2026 as services rendered compensation.

What prior sales by Robert B. Barrow in DFTX stock are disclosed?
The notice reports that during the past three months, on June 25, 2026, Robert B. Barrow sold 29,208 shares of DFTX common stock for an aggregate value of $1,230,533.04.

How many Definium Therapeutics (DFTX) shares are stated as outstanding in the filing?
The filing lists 134,366,950 shares of Definium Therapeutics, Inc. common stock as outstanding, providing context for the planned Rule 144 sale of 19,023 shares.

Which broker is handling the planned Rule 144 sale for DFTX shares?
The planned sale of 19,023 DFTX shares is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, NY, as identified in the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR